Health
AstraZeneca’s COVID-19 vaccine candidate begins late-stage U.S. study – Reuters India
AstraZeneca Plc said on Monday it has begun enrolling adults for a U.S.-funded, 30,000-subject late-stage study of its high profile COVID-19 vaccine candidate.
By Reuters Staff
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo
(Reuters) – AstraZeneca Plc said on Monday it has begun enrolling adults for a U.S.-funded, 30,000-subject late-stage study of its high profile COVID-19 vaccine candidate.
Trial participants will receive either two doses of the experimental vaccine, dubbed AZD1222, …
-
General12 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News22 hours agoRainbow Beach surfer’s untold 7/7 story
-
Noosa News12 hours agoWoman airlifted to Brisbane hospital after big cat mauling at south-east Queensland zoo near Toowoomba
-
Noosa News12 hours agoUnvaccinated horse dies from Hendra virus as Queensland records first case in three years